Major depressive disorder (MDD) is a common mental disorder characterized by long-term low mood, anhedonia, and may even lead to suicidal behavior. The development and progression of MDD involves a range of pathological alterations in the central nervous system, including dysfunction of synaptic transmission, hyper-activation of neuroinflammation, and diminished neurogenesis. The transient receptor potential vanilloid 1 (TRPV1) channel is highly expressed in brain regions associated with depression, and can regulate physiological activities such as neuroinflammation, neurogenesis, and synaptic transmission efficacy. Hence, the TRPV1 channel should be implicated in the pathogenesis of depression and be considered as a promising candidate for antidepressant treatment. This paper provides an overview of the structure and function of TRPV1 channel, with a focus on elucidating the potential mechanism of action of TRPV1 channel in depression, and explores its research trajectory and development prospects in the context of depression therapy.

Depressive disorder is a kind of mental disorder characterized by persistent and significant depressed mood, with complex etiology and high recurrence rate. At present, more precise and effective diagnostic and therapeutic approaches are still required. Increasing evidence suggests that hypoxia inducible factor-1 (HIF-1) and related pathways are involved in regulating the development and recovery of depression. HIF-1 enhances neuroplasticity, mitigates neuroinflammatory responses, alleviates oxidative stress, and modulates brain energy metabolism by influencing specific molecules associated with depression. This paper reviews pertinent domestic and international studies, examine the potential mechanisms of HIF-1 in the pathogenesis and progression of depression, and explore antidepressant treatment strategies targeting the HIF-1 signaling pathway. This article provides novel insights into elucidating the pathogenesis of depression and developing innovative therapeutic approaches.

Depressive disorder is a kind of mental disorder characterized by persistent and significant depressed mood, with complex etiology and high recurrence rate. At present, more precise and effective diagnostic and therapeutic approaches are still required. Increasing evidence suggests that hypoxia inducible factor-1 (HIF-1) and related pathways are involved in regulating the development and recovery of depression. HIF-1 enhances neuroplasticity, mitigates neuroinflammatory responses, alleviates oxidative stress, and modulates brain energy metabolism by influencing specific molecules associated with depression. This paper reviews pertinent domestic and international studies, examine the potential mechanisms of HIF-1 in the pathogenesis and progression of depression, and explore antidepressant treatment strategies targeting the HIF-1 signaling pathway. This article provides novel insights into elucidating the pathogenesis of depression and developing innovative therapeutic approaches.

Major depressive disorder (MDD) is a common mental disorder characterized by long-term low mood, anhedonia, and may even lead to suicidal behavior. The development and progression of MDD involves a range of pathological alterations in the central nervous system, including dysfunction of synaptic transmission, hyper-activation of neuroinflammation, and diminished neurogenesis. The transient receptor potential vanilloid 1 (TRPV1) channel is highly expressed in brain regions associated with depression, and can regulate physiological activities such as neuroinflammation, neurogenesis, and synaptic transmission efficacy. Hence, the TRPV1 channel should be implicated in the pathogenesis of depression and be considered as a promising candidate for antidepressant treatment. This paper provides an overview of the structure and function of TRPV1 channel, with a focus on elucidating the potential mechanism of action of TRPV1 channel in depression, and explores its research trajectory and development prospects in the context of depression therapy.

Depression is a common debilitating disorder affecting over 300 million individuals worldwide, emphasizing the pressing need to develop novel treatment targets for this disorder. Nevertheless, the pathophysiology of this disorder remains incompletely elucidated, and the currently available antidepressant treatments are suboptimal in terms of their efficacy and delayed onset of action. Thus, identifying and exploring new therapeutic avenues is of paramount importance. Recent clinical and preclinical studies have demonstrated that numerous bitter taste receptor type 2 members (Tas2Rs) agonists, including epigallocatechin gallate (EGCG), resveratrol, caffeine, humulones, and berberine, can significantly alleviate depressive symptoms in both human patients and animal models of depression. However, the precise mechanisms underlying the antidepressant effects of Tas2Rs agonists remain largely unknown. Intriguingly, a growing body of evidence suggests that Tas2Rs agonists may modulate various signaling pathways and systems including neurotransmission, inflammation, brain-gut axis, and the blood-cerebrospinal fluid barrier, all of which are believed to be implicated in the pathophysiology of depression. Therefore, this review aims to provide a comprehensive overview of the potential mechanisms of Tas2Rs agonists in depression, It synthesizes current evidence regarding its involvement in neurotransmission, inflammation, brain-gut communication, blood-cerebrospinal fluid barrier function, and other relevant pathways. This review will not only provide a valuable foundation for future research on the therapeutic potential of Tas2Rs agonists for depressive disorders but also offer new insights into the understanding of the pathophysiology of depression and the development of novel treatment strategies for this disorder.

Major depressive disorder is a common mental disorder with high rate of disability and suicide rate, but its pathogenesis remains unclear. Numerous studies indicate that energy metabolism is impaired in patients with depression, with the changes in the expression of critical genes that regulate mitochondrial homeostasis (mitochondrial biogenesis, fusion and fission, and mitophagy). Mitochondrial dysfunction, leading to reduced ATP production, oxidative stress, and inflammation, plays a significant role in the onset and development of depression, but the mechanism is still uncertain, and conflicting research findings exist. This paper reviews the intrinsic connections and potential mechanism between mitochondrial homeostasis imbalance, dysfunction, and depression, from two aspects: mitochondrial imbalance and dysfunction. It also discusses the limitations of current research, providing insight into understanding the pathogenesis of depression and developing novel mitochondrial-targeted therapeutic strategies.

As one of the most common mental disorders, depressive disorder mainly manifests as depressed mood and loss of pleasure. The occurrence and development of depressive disorder are influenced and regulated by many factors. Scientific research and clinical practices have shown that estrogen plays a crucial role in the onset and progression of depressive disorder. From adolescence, estrogen fluctuation causes gender differences in the incidence of depressive disorder between male and female patients, and the differences become even more pronounced during menopause. This paper reviewed the research progress of estrogen levels in the pathogenesis and treatment of depressive disorder to provide new directions for further research on the mechanisms of occurrence and development and the clinical treatment of the disorder.

A 22-year-old male self-administered Huoxiang Zhengqi liquid(10 mL,bid)orally due to abdominal pain and diarrhea.The symptoms improved significantly on the same day.Palpitations occurred about 30 minutes after 10 mL Huoxiang Zhengqi Liuquid administration in the morning and afternoon of the next day and in the morning of the third day,respectively,which was spontaneously relieved.Electrocardiogram showed that multiple arrhythmias alternated,including disordered atrial rhythm,paroxysmal atrial fibrillation,paroxysmal supraventricular tachycardia,frequent premature ventricular contractions,junctional premature contractions,atrioventricular block,and sinus bradycardia.After admission,the patient was given electrocardiography monitoring,polarizing fluid,verapamil injection,and other treatment methods to relieve symptoms,after 12 days of treatment,the patient's condition improved,and the electrocardiogram showed sinus rhythm.This case suggests that as an over-the-counter drug,the safety of Huoxiang Zhengqi liquid should be paid more attention by clinic and public.If patients manifest palpitation symptoms while using Huoxiang Zhengqi liquid,it is imperative to consider the potential for drug-induced serious arrhythmia and get medical treatment promptly.

Depression is a common debilitating disorder affecting over 300 million individuals worldwide, emphasizing the pressing need to develop novel treatment targets for this disorder. Nevertheless, the pathophysiology of this disorder remains incompletely elucidated, and the currently available antidepressant treatments are suboptimal in terms of their efficacy and delayed onset of action. Thus, identifying and exploring new therapeutic avenues is of paramount importance. Recent clinical and preclinical studies have demonstrated that numerous bitter taste receptor type 2 members (Tas2Rs) agonists, including epigallocatechin gallate (EGCG), resveratrol, caffeine, humulones, and berberine, can significantly alleviate depressive symptoms in both human patients and animal models of depression. However, the precise mechanisms underlying the antidepressant effects of Tas2Rs agonists remain largely unknown. Intriguingly, a growing body of evidence suggests that Tas2Rs agonists may modulate various signaling pathways and systems including neurotransmission, inflammation, brain-gut axis, and the blood-cerebrospinal fluid barrier, all of which are believed to be implicated in the pathophysiology of depression. Therefore, this review aims to provide a comprehensive overview of the potential mechanisms of Tas2Rs agonists in depression, It synthesizes current evidence regarding its involvement in neurotransmission, inflammation, brain-gut communication, blood-cerebrospinal fluid barrier function, and other relevant pathways. This review will not only provide a valuable foundation for future research on the therapeutic potential of Tas2Rs agonists for depressive disorders but also offer new insights into the understanding of the pathophysiology of depression and the development of novel treatment strategies for this disorder.

Major depressive disorder is a common mental disorder with high rate of disability and suicide rate, but its pathogenesis remains unclear. Numerous studies indicate that energy metabolism is impaired in patients with depression, with the changes in the expression of critical genes that regulate mitochondrial homeostasis (mitochondrial biogenesis, fusion and fission, and mitophagy). Mitochondrial dysfunction, leading to reduced ATP production, oxidative stress, and inflammation, plays a significant role in the onset and development of depression, but the mechanism is still uncertain, and conflicting research findings exist. This paper reviews the intrinsic connections and potential mechanism between mitochondrial homeostasis imbalance, dysfunction, and depression, from two aspects: mitochondrial imbalance and dysfunction. It also discusses the limitations of current research, providing insight into understanding the pathogenesis of depression and developing novel mitochondrial-targeted therapeutic strategies.